BIO vs ROIV · rev $651.0M vs rev $8.3M
BIO (BIO) versus Roivant Sciences Ltd (ROIV) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Roivant Sciences Ltd (ROIV) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported ROIV revenue for 2026-03-31 was $8.3M. Net income was -$299.8M. Revenue was down 71.6% from 2025-03-31 to 2026-03-31. ROIV currently screens at market cap $7.47B.
BIO currently screens at market cap $0. ROIV currently screens at market cap $7.47B.
Not investment advice. Open the BIO and ROIV stock pages for the full models.
Not investment advice.